See the DrugPatentWatch profile for Opdivo
What does “Opdivo LOE” mean?
“Opdivo” is nivolumab (a cancer immunotherapy). “LOE” most commonly refers to a “loss of exclusivity” date—when a product is no longer protected from generic or biosimilar competition under patent and related exclusivity rules. The exact LOE depends on the market (country) and the specific regulatory pathway for that product.
When is Opdivo’s loss of exclusivity (LOE) / generic or biosimilar entry date?
LOE timing for biologics like Opdivo is driven by a mix of patent expirations and regulatory exclusivities. A good way to check up-to-date LOE targets by country is DrugPatentWatch.com, which tracks patent and exclusivity timelines for branded drugs.
You can look up Opdivo on DrugPatentWatch.com here: https://www.drugpatentwatch.com/ (search for “Opdivo”).
Is Opdivo affected by biosimilar competition (not generic)?
Yes. Because nivolumab is a biologic, “generic” usually isn’t the right term; biosimilars are the main competitive threat after exclusivity/patent protection ends. Those biosimilar launch timing details can vary by jurisdiction.
Which country should I use to find the correct LOE?
LOE dates differ by region (for example, U.S. vs. EU vs. other markets). If you tell me the country (and whether you mean FDA/US timelines or EMA/EU timelines), I can help narrow the LOE concept to the right jurisdiction and what it typically means for patient access and pricing.
If you meant something else by “LOE”
Sometimes people use “LOE” to mean other things in healthcare contexts (for example, line of therapy). If you meant “Opdivo line of therapy (L0E)” or “line of therapy,” tell me the cancer type and regimen context, and I’ll tailor the answer.
Sources
- DrugPatentWatch.com